China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial People’s Hospital in the field of kidney disease. The collaboration aims to advance research and development in this critical area of healthcare. No financial details were disclosed in the partnership agreement.
Everest’s Pipeline in Kidney Disease
Everest Medicines is known for its innovative therapies in kidney disease, including Nefecon, a targeted-release formulation of budesonide for the treatment of immunoglobulin A nephropathy (IgAN). Nefecon is currently awaiting regulatory decisions in China, having been granted breakthrough therapy designation (BTD) and priority review statuses. Additionally, the company’s EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, is undergoing clinical studies for the treatment of glomerular diseases.
Enhancing Kidney Disease Treatment Options
This strategic partnership with Guangdong Provincial People’s Hospital will further strengthen Everest Medicines’ position in the kidney disease treatment landscape. By combining the expertise and resources of both organizations, the collaboration is poised to accelerate the development of new and effective therapies for patients with kidney diseases.-Fineline Info & Tech
